These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1225 related items for PubMed ID: 28114249

  • 1. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K, Daud AI.
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [Abstract] [Full Text] [Related]

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 3. Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.
    Kidwell KM, Postow MA, Panageas KS.
    Clin Cancer Res; 2018 Feb 15; 24(4):730-736. PubMed ID: 28835379
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H, Nakagawa K.
    Int J Clin Oncol; 2020 May 15; 25(5):818-830. PubMed ID: 31549270
    [Abstract] [Full Text] [Related]

  • 5. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ, Ott PA.
    Cancer Metastasis Rev; 2017 Mar 15; 36(1):43-50. PubMed ID: 28181070
    [Abstract] [Full Text] [Related]

  • 6. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E, Ascierto PA.
    J Immunotoxicol; 2012 Mar 15; 9(3):241-7. PubMed ID: 22524673
    [Abstract] [Full Text] [Related]

  • 7. Immune checkpoint blockade.
    Naidoo J, Page DB, Wolchok JD.
    Hematol Oncol Clin North Am; 2014 Jun 15; 28(3):585-600. PubMed ID: 24880949
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM, Carvajal RD.
    Curr Oncol Rep; 2017 Jul 15; 19(7):45. PubMed ID: 28508938
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Side-effects of checkpoint inhibitor-based combination therapy.
    Kourie HR, Klastersky JA.
    Curr Opin Oncol; 2016 Jul 15; 28(4):306-13. PubMed ID: 27136134
    [Abstract] [Full Text] [Related]

  • 13. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.
    Eur Urol; 2015 Aug 15; 68(2):267-79. PubMed ID: 25824720
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
    Kudo M.
    Oncology; 2017 Aug 15; 93 Suppl 1():147-159. PubMed ID: 29258079
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C, Tian J, Liu H, Li F, Niu H, Zhu B.
    Medicine (Baltimore); 2017 Jun 15; 96(26):e7325. PubMed ID: 28658143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.